Novo Nordisk A/S – Share repurchase programme
July 29, 2024 07:05 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 29 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Kraig Biocraft Laboratories Enter Rapid Growth Rearing Phase for Third Spider Silk Production Cycle
July 29, 2024 07:05 ET
|
Kraig Biocraft Laboratories
Kraig Labs (OTCQB: KBLB) entered the exponential specialized silkworm growth rearing phase for its third spider silk production cycle of the season.
PUPPIES, a Meme Coin, Will Be Listed on CoinW Exchange
July 29, 2024 07:03 ET
|
CoinW
Dubai, UAE, July 29, 2024 (GLOBE NEWSWIRE) -- CoinW, the world's pioneering cryptocurrency trading platform, will list PUPPIES, a meme coin, on the Innovation Zone. For all CoinW users, the...
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
July 29, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
DYU Launches a Vintage-Inspired E-Bike for Modern Urban Commutes, the DYU C6 Pro
July 29, 2024 07:02 ET
|
DYU
NEW YORK, NY, July 29, 2024 (GLOBE NEWSWIRE) -- DYU announces the launch of the DYU C6 Pro, bringing a classic touch to the modern urban commute. It's built to stand out from the crowd, offering...
LuxUrban Hotels Announces Agreement in Principle to Issue Up to $5.0 Million Senior Notes Due 2027
July 29, 2024 07:01 ET
|
LuxUrban Hotels
MIAMI, July 29, 2024 (GLOBE NEWSWIRE) -- LuxUrban Hotels Inc. (“LuxUrban” or the “Company”) (Nasdaq: LUXH), which secures long-term operating rights for entire hotels through Master Lease Agreements...
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
July 29, 2024 07:00 ET
|
Cognition Therapeutics, Inc.
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -- Consistent Positive Changes Across Cognitive and Functional Measures -- Favorable Safety Profile with Most...
AMG Reports Financial and Operating Results for the Second Quarter and First Half of 2024
July 29, 2024 07:00 ET
|
Affiliated Managers Group, Inc.
Company reports EPS of $2.26, Economic EPS of $4.67 in the second quarter of 2024 Net income (controlling interest) of $226 million, Economic Net Income (controlling interest) of $343 million in the...
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
July 29, 2024 07:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
July 29, 2024 07:00 ET
|
BiomX
GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...